Luas Diagnostics
Luas Diagnostics is a UK registered private company founded in 2020, focused on developing, manufacturing, and marketing rapid, point-of-care diagnostic tests for infectious diseases and other health conditions. They aim to make diagnostic testing accessible, easy-to-use, and reliable, supporting both consumers and healthcare professionals with innovative solutions. The company collaborates with global partners like Chembio Diagnostics Systems and Bond Digital Health to expand their product offerings and technological capabilities.
Industries
Nr. of Employees
small (1-50)
Luas Diagnostics
22 Great James Street, London, WC1N 3ES
Products
Sure Check HIV Self-Test
WHO prequalified and CE-marked single-use in vitro diagnostic self-test that detects antibodies to HIV-1 and HIV-2 in fingerstick whole blood; designed for at-home use with results in ~15 minutes.
Group B Streptococcus (Strepelle) home-to-lab test
Home sample collection test for prenatal screening of Group B Streptococcus to identify carriers and inform intrapartum antibiotic prophylaxis decisions.
Distributed COVID-19 antigen and IgM/IgG antibody test systems (CE-marked)
CE-marked rapid antigen test using nasal or saliva samples (results in ~20 minutes) and CE-marked rapid IgM/IgG antibody test using fingerstick or venous blood (results in ~15 minutes), with objective reader-supported semi-quantitative reporting for the antibody test.
Therapeutic Drug Monitoring tests (pipeline: lithium, theophylline, PT-INR)
Point-of-care tests in development for rapid measurement of therapeutic drug levels and anticoagulation status using a simple fingerstick and handheld reader to enable medication dose optimisation within 24 hours.
Sure Check HIV Self-Test
WHO prequalified and CE-marked single-use in vitro diagnostic self-test that detects antibodies to HIV-1 and HIV-2 in fingerstick whole blood; designed for at-home use with results in ~15 minutes.
Group B Streptococcus (Strepelle) home-to-lab test
Home sample collection test for prenatal screening of Group B Streptococcus to identify carriers and inform intrapartum antibiotic prophylaxis decisions.
Distributed COVID-19 antigen and IgM/IgG antibody test systems (CE-marked)
CE-marked rapid antigen test using nasal or saliva samples (results in ~20 minutes) and CE-marked rapid IgM/IgG antibody test using fingerstick or venous blood (results in ~15 minutes), with objective reader-supported semi-quantitative reporting for the antibody test.
Therapeutic Drug Monitoring tests (pipeline: lithium, theophylline, PT-INR)
Point-of-care tests in development for rapid measurement of therapeutic drug levels and anticoagulation status using a simple fingerstick and handheld reader to enable medication dose optimisation within 24 hours.
Services
Exclusive distribution and sales of CE-marked rapid diagnostic tests into clinical and non-clinical channels across the UK and Ireland.
Integration and deployment of a smartphone app and cloud dashboard for test result capture, semi-quantitative reporting, secure storage and multi-site management (delivered through a partnership with a digital health provider).
Research collaborations with universities for rapid assay development and validation, including work on saliva-based antigen assays and device prototyping.
Exclusive distribution and sales of CE-marked rapid diagnostic tests into clinical and non-clinical channels across the UK and Ireland.
Integration and deployment of a smartphone app and cloud dashboard for test result capture, semi-quantitative reporting, secure storage and multi-site management (delivered through a partnership with a digital health provider).
Research collaborations with universities for rapid assay development and validation, including work on saliva-based antigen assays and device prototyping.
Expertise Areas
- Point-of-care diagnostics
- Electrochemical biosensor development
- Therapeutic drug monitoring
- Rapid antigen and serology testing
Key Technologies
- Electrochemical enzyme-based biosensors
- Portable handheld readers
- Bluetooth connectivity to smartphones
- Smartphone apps and secure cloud analytics
News & Updates
Luas Diagnostics announced a partnership with Bond Digital Health to develop and market a rapid Covid-19 antibody test with integrated smartphone app and data management.
Luas Diagnostics launched a rapid test to determine immunity to Covid-19 post infection or vaccination, using a fingerstick blood sample and portable reader.
Chembio Diagnostics received CE mark approval for their SARS-CoV-2 antigen and IgM/IgG antibody test systems, which are distributed in the UK and Ireland by Luas Diagnostics.
Luas Diagnostics announced a partnership with Bond Digital Health to develop and market a rapid Covid-19 antibody test with integrated smartphone app and data management.
Luas Diagnostics launched a rapid test to determine immunity to Covid-19 post infection or vaccination, using a fingerstick blood sample and portable reader.
Chembio Diagnostics received CE mark approval for their SARS-CoV-2 antigen and IgM/IgG antibody test systems, which are distributed in the UK and Ireland by Luas Diagnostics.